NCT05576519

Brief Summary

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2017

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2017

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

October 8, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 12, 2022

Completed
20 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

October 12, 2022

Status Verified

October 1, 2022

Enrollment Period

5.4 years

First QC Date

October 8, 2022

Last Update Submit

October 8, 2022

Conditions

Ovarian Carcinoma

Keywords

Ovarian carcinomaCSCsEpCAM

Outcome Measures

Primary Outcomes (1)

  • evaluate EpCAM expression in ovarian carcinoma

    IHC

    1 month

Eligibility Criteria

Sexfemale
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Fifty paraffin blocks of EOC collected from the archive of Pathology Department of Sohag Faculty of Medicine during the time period from June 2017 to June 2022.

You may qualify if:

  • Patients with epithelial ovarian carcinoma and underwent surgery

You may not qualify if:

  • \- Cases received pre-operative chemotherapy or radiotherapy.
  • Cases with insufficient clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Faculty of Medicine, Sohag University

Sohag, Egypt

RECRUITING

Faculty of Medicine

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Central Study Contacts

Nagwa Ahmed, Lecture

CONTACT

01017415996nagwa.sadek@med.sohag.edu.eg

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer at Pathology Department, Faculty of Medicine

Study Record Dates

First Submitted

October 8, 2022

First Posted

October 12, 2022

Study Start

June 1, 2017

Primary Completion

November 1, 2022

Study Completion

December 30, 2022

Last Updated

October 12, 2022

Record last verified: 2022-10

Locations

EG(2)